Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.72 |
| ▸ | MAPK13 | O15264 | 16/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 16/20 | 0.72 |
| ▸ | MAPK11 | Q15759 | 16/20 | 0.72 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6635383 | 1.00 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11DHODH | |
| SCHEMBL6624106 | 0.89 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6621625 | 0.89 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6621630 | 0.89 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6620765 | 0.86 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6620767 | 0.86 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6621576 | 0.86 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6621579 | 0.86 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14192615 | 0.84 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6622017 | 0.84 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485167-A1 | 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS | The Procter & Gamble Company (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6677337-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | PROCTER & GAMBLE COMPANY, THE | 2003-12-04 | — | — | US | disclosed |
| WO-2003080184-A1 | 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | IL1B, IL1A, IL1R1 | MAPK14 1086/4885MAPK13 1053/4885MAPK12 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.